News
YMTX
--
0.00%
--
Yumanity Therapeutics to Present at the H.C. Wainwright Global Life Sciences Conference
Yumanity Therapeutics (Nasdaq: YMTX), a clinical-stage biopharmaceutical company focused on the discovery and development of innovative, disease-modifying therapies for neurodegenerative diseases, today announced that Richard Peters, M.D., Ph.D., President...
GlobeNewswire · 1d ago
Yumanity Therapeutics Sees Lead Candidate Interim Data From Early-Stage Parkinson's Study By Mid-2021
Benzinga · 02/10 17:02
Yumanity Initiates Dosing in Phase 1B Study in Parkinson's Disease Trial
MT Newswires · 02/10 15:43
Yumanity Therapeutics provides update on lead Parkinson’s disease clinical program
Yumanity Therapeutics (YMTX) announces that dosing has started in its Phase 1b trial of YTX-7739 in patients with Parkinson’s Disease with preliminary results expected by mid 2021.YTX-7739, Yumanity's lead clinical-stage program, is
Seekingalpha · 02/10 13:23
Yumanity Therapeutics Provides Update on Its Lead Parkinson's Disease Clinical Program, YTX-7739
Results reported of the single ascending dose study in healthy volunteers
GlobeNewswire · 02/10 13:00
Yumanity Therapeutics Files Shelf of Up to About 1.5 Million Common Shares on Behalf of Selling Stockholders
MT Newswires · 02/04 03:33
BRIEF-Yumanity Therapeutics Inc Files For Shelf Of Up To 1.5 Million Shares Of Common Stock By Selling Stockholders - SEC Filing
reuters.com · 02/03 22:23
Yumanity Therapeutics to Present at the H.C. Wainwright Virtual BioConnect Conference
Yumanity Therapeutics (Nasdaq: YMTX), a clinical-stage biopharmaceutical company focused on the discovery and development of innovative, disease-modifying therapies for neurodegenerative diseases, today announced that Paulash Mohsen, Chief Business Officer...
GlobeNewswire · 01/06 13:00
Yumanity Therapeutics to Present at the H.C. Wainwright Virtual BioConnect Conference
Yumanity Therapeutics (Nasdaq: YMTX), a clinical-stage biopharmaceutical company focused on the discovery and development of innovative, disease-modifying therapies for neurodegenerative diseases, today announced that Paulash Mohsen, Chief Business Officer...
GlobeNewswire · 01/06 13:00
Yumanity Therapeutics to Present at the H.C. Wainwright Virtual BioConnect Conference
BOSTON, Jan. 06, 2021 (GLOBE NEWSWIRE) -- Yumanity Therapeutics (Nasdaq: YMTX), a clinical-stage biopharmaceutical company focused on the discovery and development of innovative, disease-modifying therapies for neurodegenerative diseases, today announced t...
GlobeNewswire · 01/06 13:00
Yumanity Therapeutics to Present at the H.C. Wainwright Virtual BioConnect Conference
BOSTON, Jan. 06, 2021 (GLOBE NEWSWIRE) -- Yumanity Therapeutics (Nasdaq: YMTX), a clinical-stage biopharmaceutical company focused on the discovery and development of innovative, disease-modifying therapies for neurodegenerative diseases, today announced t...
GlobeNewswire · 01/06 13:00
Anthony Coles Reports 8.2% Stake In Yumanity Therapeutics As Of Dec. 22
-SEC Filing
SEC Filing · 01/04 21:19
The Daily Biotech Pulse: FDA Nod For Amphastar's Generic Glucagon, Arcturus Sinks On Vaccine Data, Decision Day For Osmotica
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Dec. 28)
Benzinga · 12/29/2020 13:09
Yumanity Therapeutics Completes Reverse Merger with Proteostasis Therapeutics
Shares of Yumanity to commence trading on Nasdaq under new ticker symbol "YMTX" on December 23, 2020
GlobeNewswire · 12/23/2020 17:43
Yumanity Therapeutics Completes Reverse Merger with Proteostasis Therapeutics
Shares of Yumanity to commence trading on Nasdaq under new ticker symbol "YMTX" on December 23, 2020
GlobeNewswire · 12/23/2020 17:43
Yumanity Therapeutics Completes Reverse Merger with Proteostasis Therapeutics
Shares of Yumanity to commence trading on Nasdaq under new ticker symbol "YMTX" on December 23, 2020
GlobeNewswire · 12/23/2020 17:43
Proteostasis Therapeutics completes merger with Yumanity Therapeutics, effects 1-for-20 reverse stock split
Proteostasis Therapeutics ([[PTI]]) and Yumanity Therapeutics have completed its reverse merger.The combined company will operate under the name Yumanity Therapeutics and its shares will commence trading on the Nasdaq Capital Market on December 23,
Seekingalpha · 12/23/2020 15:11
Proteostasis Therapeutics Stockholders Approve Business Combination With Yumanity Therapeutics; Board Sets Reverse Stock Split Ratio Of 1-For-20; Sets Reverse Split Date For Today At 12 p.m. EST
Proteostasis Therapeutics, Inc. Stockholders Approve Business Combination with Yumanity Therapeutics, Inc.; Board Sets Reverse Stock Split Ratio BOSTON, Dec. 22, 2020 /PRNewswire/ -- Proteostasis
Benzinga · 12/22/2020 15:53
Proteostasis Therapeutics, Inc. Stockholders Approve Business Combination with Yumanity Therapeutics, Inc.; Board Sets Reverse Stock Split Ratio
, /PRNewswire/ -- Proteostasis Therapeutics, Inc. ("Proteostasis") (Nasdaq: PTI) announced today that, based on the final vote count certified by the inspector of elections at its reconvened special meeting of stockholders held at on (the "Special Meeting"), its stockholders approved all of the proposals related to the merger (the "Merger") as contemplated by the Agreement and Plan of Merger and Reorganization, dated , as amended, by and among Proteostasis, Yumanity Holdings, LLC ("Holdings"), Yumanity Therapeutics, Inc. ("Yumanity"), a wholly-owned subsidiary of Holdings, and Pangolin Merger Sub, a wholly-owned subsidiary of Proteostasis ("Merger Sub") (the "Merger Agreement"), including (i) the issuance of Proteostasis common stock in the Merger in accordance with the terms of the Merger Agreement; (ii) a reverse stock split of Proteostasis common stock, at a ratio of one new share for every 20 to 30 shares outstanding, with the exact ratio and effective time of the reverse stock split to be determined by the Proteostasis board of directors and publicly announced by press release; and (iii) an amendment to the Proteostasis certificate of incorporation to effect the change of name from "Proteostasis Therapeutics, Inc." to "Yumanity Therapeutics, Inc." Also approved was the compensation that will or may become payable by Proteostasis to its named executive officers in connection with the Merger, on a non-binding advisory vote basis.
PR Newswire - PRF · 12/22/2020 15:48
Proteostasis Therapeutics, Inc. Stockholders Approve Business Combination with Yumanity Therapeutics, Inc.; Board Sets Reverse Stock Split Ratio
, /PRNewswire/ -- Proteostasis Therapeutics, Inc. ("Proteostasis") (Nasdaq: PTI) announced today that, based on the final vote count certified by the inspector of elections at its reconvened special meeting of stockholders held at on (the "Special Meeti...
PR Newswire - PRF · 12/22/2020 15:48
Webull provides a variety of real-time YMTX stock news. You can receive the latest news about Yumanity Therapeutics Inc through multiple platforms. This information may help you make smarter investment decisions.
About YMTX
Yumanity Therapeutics Inc, formerly Proteostasis Therapeutics, Inc., is a clinical-stage biopharmaceutical company. The Company is engaged in treatment of neurodegenerative diseases through its scientific foundation and drug discovery platform. The platform is designed to enable the Company to screen for potential disease-modifying therapies by overcoming toxicity of misfolded proteins in neurogenerative diseases. The Company's product candidate, YTX-7739, is in Phase 1 clinical development for Parkinson's disease and YTX-9184, in IND-enabling studies for Dementia with Lewy Bodies. The Company’s pipeline consists of additional programs focused on multi- system atrophy, amyotrophic lateral sclerosis (ALS or Lou Gehrig's disease), frontotemporal lobar dementia (FTLD), and Alzheimer's disease.